On 14 October 2026 the FDA recorded a supplement to the biologics licence application for etanercept (Enbrel). The public record does not describe what the supplement changes; supplements to biologic licences commonly cover manufacturing, device or labelling updates.
Nothing in the notice indicates a new safety concern or a change in indications. Etanercept biosimilars are separately licensed, and their status is unaffected by this record.
- This is an administrative supplement to the etanercept licence, not a safety communication.
- No change in indication or warnings is described.
- Biosimilar etanercept products are licensed separately.
- Continue routine infection screening and monitoring for patients on etanercept.
Why it matters
It keeps the regulatory record for a widely used TNF inhibitor visible to prescribers.
Don't overread it
A licence supplement is not a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free